Invesco Pharmaceuticals ETF
PJP
88 hedge funds and large institutions have $61.3M invested in Invesco Pharmaceuticals ETF in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 24 reducing their positions, and 8 closing their positions.
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
7% more funds holding
Funds holding: 82 → 88 (+6)
2.57% more ownership
Funds ownership: 14.78% → 17.35% (+2.6%)
6% less capital invested
Capital invested by funds: $65M → $61.3M (-$3.64M)
21% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$484K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$474K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$312K |
| 4 |
BCA
Bay Colony Advisors
Concord,
Massachusetts
|
+$265K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$227K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$2.28M |
| 2 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$1.33M |
| 3 |
Citigroup
New York
|
-$517K |
| 4 |
FTUS
Flow Traders U.S.
New York
|
-$469K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$246K |
PJP Hedge Fund Activity: Q1 2022 in Review
88 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q1 2022, worth a combined $61.3M — down 5.6% from $65M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PJP positions and 8 closed out — a net gain of 7 holders — while 19 added to existing stakes and 24 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $484K. The largest seller was Wells Fargo, cutting an estimated $2.28M.
- 88 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q1 2022, up from 82 in Q4 2021.
- Funds reported $61.3M of Invesco Pharmaceuticals ETF stock for Q1 2022, down 5.6% quarter-over-quarter.
- 15 funds opened new Invesco Pharmaceuticals ETF positions in Q1 2022 and 8 closed out, a net change of +7 holders.
- The largest Invesco Pharmaceuticals ETF buyer in Q1 2022 was Susquehanna International Group, an estimated $484K added.
- The largest Invesco Pharmaceuticals ETF seller in Q1 2022 was Wells Fargo, an estimated $2.28M sold.
Based on aggregated 13F filings for Q1 2022.